fda warning letter hims & hers compounded semaglutide september 2025 U.S. sends drug advertising letters to Lilly, Novo, Hims and Hers warns investors

WBUR reported that Massachusetts will end MassHealth coverage for GLP-1 weight (Photo illustration by Mario Tama/Getty Images) Thousands of Massachusetts residents are days away from losing insurance coverage for powerful weight loss drugs to manage obesity

Heres whats coming soon, and whats in clinical trials: Orforglipron (brand name Foundayo): A once-daily oral GLP-1 was just approved by the FDA for weight loss, and will hopefully be approved for type 2 diabetes soon

Wang M, Wang C, Chen M, Xi Y, Cheng W, Mao C, et al

Physician interaction is minimal compared to specialized clinics

To preserve long-term benefits, its crucial to combine GLP-1 medications with lasting lifestyle adjustments

-